Slideshows Images Quizzes

Dilatrate SR

Last reviewed on RxList: 6/20/2017
Dilatrate SR Side Effects Center

Last reviewed on RxList 6/20/2017

Dilatrate-SR (isosorbide dinitrate) Sustained Release is a vasodilator used to prevent angina pectoris due to coronary artery disease. Common side effects of Dilatrate-SR include:

Every dosing regimen for organic nitrates including Dilatrate-SR must provide a daily nitrate-free interval to avoid the development of tolerance. To achieve the necessary nitrate-free interval, at least one of the daily interdose intervals must be at least 14 hours long. Do not exceed 160 mg (4 capsules) per day. Dilatrate-SR may interact with phosphodiesterase inhibitors, riociguat, alcohol, and other vasodilators. Tell your doctor all medications and supplements you use. During pregnancy, Dilatrate-SR should be taken only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Dilatrate-SR (isosorbide dinitrate) Sustained Release Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Dilatrate SR Professional Information


Adverse reactions to isosorbide dinitrate are generally dose related, and almost all of these reactions are the result of isosorbide dinitrate's activity as a vasodilator. Headache, which may be severe, is the most commonly reported side effect. Headache may be recurrent with each daily dose, especially at higher doses. Transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. Hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. Syncope, crescendo angina, and rebound hypertension have been reported but are uncommon.

Extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normalseeming patients. Methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred (see OVERDOSAGE).

Data are not available to allow estimation of the frequency of adverse reactions during treatment with Dilatrate®-SR sustained release capsules.

Read the entire FDA prescribing information for Dilatrate SR (Isosorbide Dinitrate Sustained Release Capsules)

Related Resources for Dilatrate SR

Related Health

Related Drugs

© Dilatrate SR Patient Information is supplied by Cerner Multum, Inc. and Dilatrate SR Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors